NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) announced it received first place in the Healthcare category at the BOLD Awards VII Gala held March 27, 2026, in Barcelona, recognizing its leadership in exosome-based therapies for central nervous system injuries. The company also provided a corporate update highlighting its selection by a panel of global industry leaders, underscoring the significance of its innovative approach to treating spinal cord and optic nerve injuries.
The company further reported plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval, to support investor awareness efforts beginning April 1, 2026. This engagement includes distribution of news and updates across more than 5,000 outlets, with a monthly fee of $6,500 under a one-year agreement aimed at strengthening market visibility and long-term shareholder value. The partnership with IBN, a specialized communications platform, is expected to enhance NurExone's reach to a wide audience of investors and stakeholders, leveraging IBN's network of wire solutions, editorial syndication, and social media distribution.
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.
The award and investor outreach initiatives come at a critical time for the company as it advances its clinical pipeline. The recognition from the BOLD Awards VII Healthcare category validates the potential of its exosome-based platform, which could address significant unmet medical needs in CNS injuries. The engagement with IBN is part of a broader strategy to increase awareness among the investment community and support the company's market valuation. For more information, visit NurExone's website.
